• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.

    5/21/25 4:11:12 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001873507
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Ginkgo Bioworks Holdings, Inc.
    SEC File Number
    001-40097
    Address of Issuer
    27 DRYDOCK AVENUE
    8TH FLOOR
    BOSTON
    MASSACHUSETTS
    02210
    Phone
    (877) 442-5362
    Name of Person for Whose Account the Securities are To Be Sold
    Dmytruk Mark E.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    7065354.794634463005/21/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A05/20/2025Restricted Stock VestingIssuerCheckbox not checked70605/20/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Mark Dmytruk
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A03/04/20257906102.91
    Mark Dmytruk
    27 Drydock Avenue
    8th Floor
    Boston � MA � 02210
    Class A04/21/202512449059.69

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    05/21/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Bradley Camilo, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Mark Dmytruk

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $DNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ginkgo Bioworks downgraded by BTIG Research

    BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

    5/15/24 7:33:13 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by William Blair

    William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

    5/10/24 7:33:29 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by Raymond James with a new price target

    Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

    11/14/23 9:04:22 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Second Quarter 2025 Fina

    8/7/25 5:01:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON, July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgob

    7/31/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    SEC Filings

    View All

    SEC Form EFFECT filed by Ginkgo Bioworks Holdings Inc.

    EFFECT - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    8/15/25 12:15:24 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Ginkgo Bioworks Holdings Inc.

    S-3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    8/7/25 5:12:02 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.

    10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    8/7/25 5:05:04 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Coen Steven P. converted options into 2,547 shares and sold $10,669 worth of shares (1,084 units at $9.84), increasing direct ownership by 16% to 10,679 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    7/21/25 4:28:30 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Potter Myrtle S converted options into 10,822 shares (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    6/13/25 4:24:04 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hannan Kathy Hopinkah converted options into 10,822 shares, increasing direct ownership by 259% to 15,003 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    6/13/25 4:19:19 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/16/24 5:08:50 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/14/24 5:16:23 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Reports Second Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON, Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Second Quarter 2025 Fina

    8/7/25 5:01:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON, July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgob

    7/31/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Reports First Quarter 2025 Financial Results

    Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

    5/6/25 5:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Leadership Updates

    Live Leadership Updates

    View All

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

    BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", or the ", Company", )), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting

    5/21/25 4:05:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

    Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

    5/14/24 6:00:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/12/24 3:58:52 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/4/24 11:56:06 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care